Yale Ventures

Oversubscribed round led by 4BIO Capital includes strategic investment from AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund, reflecting depth of industry interest in this novel RNA therapeutics platform Financing will support proof of concept in hepatocellular carcinoma and advancement of follow-on programs including colorectal cancer Cloverleaf’s tRNA therapeutic platform, has demonstrated significantly greater potency and selectivity for cancer cells over healthy tissue in...

CORE Timber is rethinking how buildings get built, sourcing wood from regeneratively managed regional forests and using robotically fabricated mass timber structural components to turn construction into a climate solution. The building sector is one of the largest sources of carbon emissions globally while forests, best positioned to offset that damage, continue to be undervalued by construction markets and degraded through exploitation, mismanagement, and neglect.

Source: Hidden Switch in Cell Division May Point to New Cancer Treatments

Latent Bio resides at the intersection of geometric deep learning, chemistry, biology, and clinical data—reimagining how drugs are discovered and optimizing translation to and through the clinic. With scientific roots in Yale's Krishnaswamy Lab, Latent Bio is implementing practical, business-focused, applications of GDL for drug discovery, biomarker discovery, and characterization of clinical populations to optimize assets for clinical development and partnerships.

Source: How the Right Business Model Can Fuel Creativity

Source: Student founders to bring startup incubator from San Francisco to Yale

Have an idea? Submit your innovation to Yale Ventures

Have an idea? Submit your innovation to Yale Ventures

Source: Yale researchers to help lead NSF Center studying how robots and people learn to live and work together

Saying ‘YES’ to entrepreneurship at Yale